Medivir and Cancer Research Technology collaborate to develop new class of cancer drugs

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) and Cancer Research
Technology (CRT), Cancer Research UK’s commercialization and development arm,
today jointly announce a partnership to develop a new class of drugs that has
shown promise for treating a range of different cancers, including pancreatic
cancer.

As part of the collaboration, CRT and Medivir will conduct a two-year research
programme to optimize and develop small molecules targeting the cell surface
protein ADAM8, which has been linked to tumour survival, cell invasion and
metastasis.

Under the terms of the agreement Medivir receives an exclusive, global license
to research, develop, manufacture and commercialize ADAM8 inhibitor drugs
resulting from development. CRT receives an upfront payment and future success
milestones as well as royalties on sales which are shared with the academic
collaborators.

Blocking ADAM8 in mice with pancreatic cancer prevented the spread of the
disease, shrunk tumours and significantly extended lifespan. This is thought to
be due to its involvement in cell adhesion, cell migration, inflammation and the
growth of blood vessels – key processes that many cancers rely on for growth and
development. High levels of the protein have been linked with more aggressive
tumours including those in pancreatic, breast, brain, prostate, lung, head and
neck, and kidney cancers.

This research will be led by Professor Jörg Bartsch as head of the TransMIT
-Project Division for Research in Neuro-Oncology at TransMIT GmbH, located at
Marburg University in Germany, in collaboration with Medivir. Prof. Bartsch
previously worked at King’s College London where the initial patent application
was filed by King’s College IP and Licensing team. Further proof of concept
studies were funded by Cancer Research UK at King’s College.

“We are very glad and excited to see this collaboration come to life. The
synergy of expertise between Medivir and our Laboratory forms an excellent
platform for successful exploration of this first-in-class approach to targeted
therapy against ADAM8. This really is “bench-to bedside” research at its best,”
said Professor Bartsch.

“This collaboration is a demonstration of our commitment to advance oncology
drug discovery at Medivir and we are pleased to partner with such a renowned
institution such as Cancer Research UK, and with Professor Bartsch, a leading
researcher in the field,” said Niklas Prager, Medivir’s CEO.

Dr Keith Blundy, Cancer Research Technology’s chief executive officer,
continues: “Medivir’s significant expertise in protease inhibitor design coupled
with CRT’s proven track record in drug development will hopefully pave the way
for an exciting new class of drugs for treating cancer. Exploratory studies
indicate that ADAM8 is an attractive target across many types of cancer, and
potentially other diseases driven by inflammation, and we look forward to
further exploring that promise through this innovative collaboration.”

For further information, please contact:
Ola Burmark, CFO Medivir AB, mobil: +46 (0)725-480 580.

Medivir is required under the Securities Markets Act to make the information in
this press release public.
The information was submitted for publication at 08.30 CET on 13 April 2015.

About Medivir
Medivir is a research based pharmaceutical company with a research focus on
infectious diseases and oncology. We have a leading competence within protease
inhibitor design and nucleotide/nucleoside science and we are dedicated to
develop innovative pharmaceuticals that meet great unmet medical need. Our
commercial organization provides a growing portfolio of specialty care
pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm
Mid Cap List.

About Cancer Research Technology
Cancer Research Technology (CRT) is a specialist commercialisation and
development company, which aims to develop new discoveries in cancer research
for the benefit of cancer patients. CRT works closely with leading international
cancer scientists and their institutes to protect intellectual property arising
from their research and to establish links with commercial partners. CRT
facilitates the discovery, development and marketing of new cancer therapeutics,
vaccines, diagnostics and enabling technologies. CRT is a wholly owned
subsidiary of Cancer Research UK, the world's leading cancer charity dedicated
to saving lives through research. Further information about CRT can be found at
www.cancertechnology.com.

About Cancer Research UK
Cancer Research UK is the world’s leading cancer charity dedicated to saving
lives through research. Cancer Research UK’s pioneering work into the
prevention, diagnosis and treatment of cancer has helped save millions of lives.
Cancer Research UK receives no government funding for its life-saving research.
Every step it makes towards beating cancer relies on every pound donated. Cancer
Research UK has been at the heart of the progress that has already seen survival
rates in the UK double in the last forty years. Today, 2 in 4 people survive
cancer. Cancer Research UK’s ambition is to accelerate progress so that 3 in 4
people will survive cancer within the next 20 years. Cancer Research UK supports
research into all aspects of cancer through the work of over 4,000 scientists,
doctors and nurses. Together with its partners and supporters, Cancer Research
UK's vision is to bring forward the day when all cancers are cured. For further
information about Cancer Research UK's work or to find out how to support the
charity, please call 0300 123 1022 or visit www.cancerresearchuk.org.